Imperial College London
Alternate

ProfessorMatthewPickering

Faculty of Medicine, Department of Immunology and Inflammation

Centre Director, Professor of Rheumatology
 
 
 
//

Contact

 

matthew.pickering Website

 
 
//

Assistant

 

Miss Claudia Rocchi +44 (0)20 3313 2315

 
//

Location

 

9N12Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Medjeral-Thomas:2021:10.1097/MNH.0000000000000705,
author = {Medjeral-Thomas, NR and Pickering, MC and Cook, HT},
doi = {10.1097/MNH.0000000000000705},
journal = {Curr Opin Nephrol Hypertens},
pages = {310--316},
title = {Complement and kidney disease, new insights.},
url = {http://dx.doi.org/10.1097/MNH.0000000000000705},
volume = {30},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE OF REVIEW: In this review, we discuss recent studies showing the importance of the complement pathway in kidney disease. RECENT FINDINGS: Recent findings in C3 glomerulopathy (C3G) include: acute postinfectious glomerulonephritis is characterised by the presence of antifactor B antibodies; human leukocyte antigen type, but not rare complement gene variation, is associated with primary immunoglobulin-associated membranoproliferative GN and C3G. Immunohistochemistry in C3G shows that factor H related protein 5 (FHR5) is the most prevalent complement protein and correlates with kidney function. A multicentre study supported the use of mycophenolate mofetil (MMF) in C3G even after a propensity matching analysis. In immunoglobulin A nephropathy (IgAN) several studies have emphasised the importance of complement. Imbalances of circulating FH and FHR1 and FHR5, which interfere with the regulatory functions of FH, associate with IgAN. Immunohistochemistry has shown associations between glomerular FHR5 deposition and C3 activation; glomerular FHR5 associated with clinical markers of IgAN severity. Data also suggest the lectin complement pathway contributes to IgAN severity. We also discuss complement activation in thrombotic microangiopathy and other kidney diseases. SUMMARY: Complement activity can be detected in a wide range of kidney diseases and this provides pathogenic insight and potential for therapy with the ongoing development of several drugs directed at complement activation.
AU  - Medjeral-Thomas,NR
AU  - Pickering,MC
AU  - Cook,HT
DO  - 10.1097/MNH.0000000000000705
EP  - 316
PY  - 2021///
SP  - 310
TI  - Complement and kidney disease, new insights.
T2  - Curr Opin Nephrol Hypertens
UR  - http://dx.doi.org/10.1097/MNH.0000000000000705
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33767058
VL  - 30
ER  -
Download